During its earnings call this week, the liquid biopsy firm said it is planning a 10,000-patient trial to test its Lunar assay for colorectal cancer screening.
The company presented new data on the performance of a multi-pronged liquid biopsy assay in detecting colorectal cancers across a range of clinical stages.
Following promising data from its Circulating Cell-free Genome Atlas study, the firm decided to pivot its breast cancer trial to support its multi-cancer test.
Investigators, led by Hong Kong researcher and Grail collaborator Dennis Lo, described a cancer detection strategy using cleavage patterns in circulating DNA molecules.
Though there are few direct hints at how the company plans to translate its findings to a clinical test, its early data has captured the attention of the cancer community.
